# An Evaluation AZD2014 Alone and in Combination With Rituximab in Relapsed/Refractory Diffuse Large B Cell Lymphoma

> **NCT02752204** · PHASE2 · COMPLETED · sponsor: **University of Birmingham** · enrollment: 36 (actual)

## Conditions studied

- Diffuse Large B-Cell Lymphoma

## Interventions

- **DRUG:** AZD 2014
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT02752204
- **Lead sponsor:** University of Birmingham
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10
- **Primary completion:** 2017-09-07
- **Final completion:** 2020-02-06
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2020-11-05

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02752204

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02752204, "An Evaluation AZD2014 Alone and in Combination With Rituximab in Relapsed/Refractory Diffuse Large B Cell Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02752204. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*